Bayer has provided guidance for Finerenone's peak sales, projecting it could reach more than €4 billion (approximately $4.3 billion USD) annually. This forecast is based on the drug's potential across various chronic kidney disease (CKD) and cardiovascular indications. The company anticipates that Finerenone could achieve this peak sales level in 2026 [1].
What is Finerenone used for?
Finerenone, marketed as Kerendia by Bayer, is a medication prescribed to reduce the risk of sustained decline in kidney function, kidney failure, cardiovascular death, non-fatal heart attack, and non-fatal stroke in adults with chronic kidney disease (CKD) associated with type 2 diabetes [2]. It works by blocking the detrimental effects of the overactive mineralocorticoid receptor (MR) pathway, which is implicated in CKD and cardiovascular disease progression [3].
When did Finerenone receive approval?
Finerenone received its first major regulatory approval in the United States by the Food and Drug Administration (FDA) in July 2021 for the treatment of adult patients with chronic kidney disease (CKD) associated with type 2 diabetes [2]. Approval in the European Union followed in January 2022 [4].
How does Finerenone's sales forecast compare to other Bayer drugs?
Bayer has highlighted Finerenone as a key growth driver. The €4 billion peak sales projection places it among Bayer's most significant pharmaceutical products. While specific comparative figures for other Bayer drugs' current or projected sales are not detailed here, the substantial guidance for Finerenone indicates its strategic importance to the company's pharmaceutical division [1].
What is the patent situation for Finerenone?
Information regarding the specific patent expiry dates for Finerenone is available through patent tracking resources. Companies like DrugPatentWatch.com track these patents, which are crucial for understanding the timeline for potential generic competition [5]. The patent landscape will influence the duration of Finerenone's market exclusivity and the timing of generic entry.